Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terfenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-Terfenadine SCHEMBL155924 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5999023 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11857869 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5999024 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5998456 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| R-Terfenadine SCHEMBL17732284 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL11546558 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL27965234 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL17732283 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11871354 | 0.98 | KCNH2 (0.96) | KCNH2LMNAHRH1DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 27401 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| EP-0311067-A1 | Pharmaceutical composition for piperidinoalkanol-decongestant combination | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-04-12 | — | — | EP | claimed |
| WO-1988009656-A1 | COUGH/COLD MIXTURES COMPRISING NON-SEDATING ANTIHISTAMINE DRUGS | SUNSHINE ABRAHAM (US) | 1988-12-15 | — | — | WO | claimed |
| US-4783465-A | Cough/cold mixtures comprising non-sedating antihistamine drugs | ANALGESIC ASSOCIATES (US) | 1988-11-08 | — | — | US | claimed |
| WO-1988008302-A1 | COUGH/COLD MIXTURES COMPRISING NON-SEDATING ANTIHISTAMINE DRUGS | SUNSHINE ABRAHAM (US) | 1988-11-03 | — | — | WO | claimed |
| US-4742175-A | Preparation of polymorphically pure terfenadine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | claimed |
| CN-85106652-A | Preparation method of antihistamine hot melt formula | — | 1987-03-25 | — | — | CN | claimed |
| EP-0111144-B1 | SUSTAINED RELEASE SOLID DOSAGE FORMS HAVING NON-UNIFORM DISTRIBUTION OF ACTIVE INGREDIENT | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-12-03 | — | — | EP | claimed |
| EP-0173293-A2 | Hot melt antihistamine formulations | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-03-05 | — | — | EP | claimed |
| EP-0111144-A1 | Sustained release solid dosage forms having non-uniform distribution of active ingredient | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-06-20 | — | — | EP | claimed |
| US-3966949-A | LIQUID LIPOPHILIC FATTY ACID SALT | RICHARDSON-MERRELL INC. (US) | 1976-06-29 | — | — | US | claimed |